Zelluna ASA's Financial Results and Business Update
Zelluna ASA, a pioneer in allogeneic T-cell receptor (TCR) therapies to combat cancer, recently announced its financial outcomes for the second quarter of 2025. The detailed results shed light on the company's commitment to developing innovative cancer treatments that integrate the immune system's natural defenses.
Business Highlights from Q2 2025
The second quarter of 2025 showcased several key developments for Zelluna ASA. The company is progressing toward its goal of submitting an Investigational New Drug (IND) application or Clinical Trial Application (CTA) in the latter half of 2025. This is an important step that will pave the way for initiating first-in-human clinical trials by the first half of 2026.
Regulatory Engagement and Manufacturing Initiatives
After receiving positive pre-IND feedback from the FDA, Zelluna broadened its regulatory efforts by submitting a scientific advice package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, focusing on its ZI-MA4-1 product. This proactive approach demonstrates the company's strategic thinking in advancing its development process.
Advancements in Clinical Readiness
Moreover, Zelluna has initiated Good Manufacturing Practice (GMP) production of clinical materials as of July 2025, marking a crucial milestone in its clinical development efforts. This scalable manufacturing platform, developed in collaboration with Catalent, is designed to produce hundreds of doses from a single batch, thus enhancing operational efficiency.
Support from Clinical Experts
Additionally, Zelluna has garnered substantial backing from leading clinical experts and research sites. This has allowed the company to refine its trial design effectively and enhance operational readiness ahead of its IND submission.
Financial Overview
In terms of financial performance, Zelluna’s total operating expenses reached MNOK 38.4 during Q2 2025, with a year-to-date total of MNOK 67.8. The overall loss for the quarter stood at MNOK 37.5, bringing the year-to-date total to MNOK 66.0.
Cash Flow and Financial Runway
Net cash flow from operations was notably negative at MNOK 59.4 for Q2 2025. Excluding currency effects, the decline in cash and cash equivalents was MNOK 59.0 during the same period. As of June 30, 2025, Zelluna reported cash and equivalents amounting to MNOK 76.0. The current financial resources are anticipated to sustain operations into Q2 2026, though this window was slightly adjusted due to one-off costs associated with advancing the TCR-NK manufacturing process. However, expectations remain that the cash burn rate will decrease significantly moving forward.
Recent Share Issuance
On May 27, 2025, Zelluna ASA issued 227,096 new shares at NOK 26 each to fulfill an option exercise fee of EUR 500,000 related to Inven2. This strategic financial maneuver reflects the company’s ongoing efforts to solidify its fiscal health as it pursues aggressive growth in clinical development.
Looking Ahead
The company plans to release its detailed quarterly report and presentation on August 20, 2025, at 07:00 CET, with resources accessible on the Zelluna website. Following the presentation, a webcast will be held at 09:00 CET, providing an opportunity for stakeholders to engage and submit questions for follow-up.
Contact Information
For additional information or inquiries, please reach out to:
Namir Hassan, CEO
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608
Hans Vassgård Eid, CFO
Email: hans.eid@zelluna.com
Phone: +47 482 48632
About Zelluna ASA
Zelluna is on a mission to deliver transformative cancer treatments with the potential to cure advanced solid tumors safely and affordably at a global scale. The company combines the most effective components of the immune system by developing pioneering "off-the-shelf" T-cell receptor (TCR) guided natural killer (NK) cell therapies. Their unique TCR-NK platform aims to overcome the challenges posed by the variability of tumors and enhance patient access to effective treatments.
Frequently Asked Questions
What is Zelluna ASA focused on?
Zelluna ASA is focused on developing innovative T-cell receptor-based therapies for cancer treatment.
What were the key highlights from Q2 2025 for Zelluna ASA?
The key highlights include readiness for IND submission and significant progress in GMP manufacturing.
How have the financials shaped Zelluna's outlook?
Despite a net cash outflow, ongoing plans to streamline costs and a positive runway into Q2 2026 offer a favorable outlook.
When is the upcoming webcast scheduled for Zelluna ASA?
The webcast is scheduled for August 20, 2025, at 09:00 CET.
How does Zelluna ASA intend to support its clinical development?
Zelluna ASA seeks to engage actively with regulatory agencies and leverage expert support to enhance its clinical trial designs.
